Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Fevzi Ozkaynak

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Frontiers in Immunology

Allergy

Immunology

2018

English

Related publications

Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study

Journal of Clinical Oncology

English

Anti‐GM‐CSF Therapy in Psoriasis

British Journal of Dermatology

Dermatology

Medicine

2019

English

Myeloablative Allogeneic Bone Marrow Transplant Using T Cell Depleted Allografts Followed by Post-Transplant GM-CSF in High-Risk Myelodysplastic Syndromes

English

Isotretinoin Is a Safety Therapy on Kidney: A Retrospective Study

Turk Dermatoloji Dergisi

Dermatology

2018

English

Improved Survival of Children With Advanced Neuroblastoma Treated by Intensified Therapy Including Myeloablative Chemotherapy With Stem Cell Transplantation: A Retrospective Analysis From the Tohoku Neuroblastoma Study Group.

Tohoku Journal of Experimental Medicine

English

GM-CSF Therapy in Pulmonary Alveolar Proteinosis

English

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients With Advanced Solid Tumors

Clinical Cancer Research

Cancer Research

Oncology

2011

English

665. Toxicity and Bio-Distribution of a GM-CSF-Expressing, Chimeric Oncolytic Adenovirus ONCOS-102

English

Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group D9602 Study

International Journal of Radiation Oncology Biology Physics

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Fevzi Ozkaynak

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Related publications

Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study

Anti‐GM‐CSF Therapy in Psoriasis

Myeloablative Allogeneic Bone Marrow Transplant Using T Cell Depleted Allografts Followed by Post-Transplant GM-CSF in High-Risk Myelodysplastic Syndromes

Isotretinoin Is a Safety Therapy on Kidney: A Retrospective Study

Improved Survival of Children With Advanced Neuroblastoma Treated by Intensified Therapy Including Myeloablative Chemotherapy With Stem Cell Transplantation: A Retrospective Analysis From the Tohoku Neuroblastoma Study Group.

GM-CSF Therapy in Pulmonary Alveolar Proteinosis

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients With Advanced Solid Tumors

665. Toxicity and Bio-Distribution of a GM-CSF-Expressing, Chimeric Oncolytic Adenovirus ONCOS-102

Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group D9602 Study